[HTML][HTML] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
[HTML][HTML] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX …
Background Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer
On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with
metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 …
metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 …
[HTML][HTML] Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6 …
Background Afatinib is approved in the US, Europe, and several other regions for first-line
treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell …
treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell …
Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.
7525^ Background: Despite initial responses to reversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors,(erlotinib or gefitinib), all non-small cell lung cancer …
(EGFR) tyrosine kinase inhibitors,(erlotinib or gefitinib), all non-small cell lung cancer …
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor …
Abstract Objective Approximately 10%–15% patients with epidermal growth factor receptor
(EGFR) mutations harbor non-classical mutations. However, the effects of EGFR-tyrosine …
(EGFR) mutations harbor non-classical mutations. However, the effects of EGFR-tyrosine …
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR …
8016 Background: A is an oral, irreversible, ErbB Family Blocker, blocking signaling from
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in …
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in …
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review
J Köhler, M Schuler - Onkologie, 2013 - karger.com
Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …
[HTML][HTML] Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
Introduction Previously, we developed a database of 693 patients with NSCLC and
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …
Common EGFR-Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase Inhibitors
Ten years ago, somatic mutations in EGFR were identified in patients with non-small-cell
lung cancer. Demonstration of the antitumor efficacy of EGF receptor-directed tyrosine …
lung cancer. Demonstration of the antitumor efficacy of EGF receptor-directed tyrosine …